首页> 美国卫生研究院文献>International Journal of Clinical and Experimental Pathology >Detection of EGFR mutation in supernatant cell pellets of pleural effusion and tumor tissues from non-small cell lung cancer patients by high resolution melting analysis and sequencing
【2h】

Detection of EGFR mutation in supernatant cell pellets of pleural effusion and tumor tissues from non-small cell lung cancer patients by high resolution melting analysis and sequencing

机译:高分辨率融合分析和测序检测非小细胞肺癌患者上清液胸腔积液细胞团和肿瘤组织中的EGFR突变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To determine epidermal growth factor receptor (EGFR) mutation in advanced non-small cell lung cancer (NSCLC) patients and compare the detection efficiency between different sample resources, both high resolution melting (HRM) analysis and direct sequencing method were used to analyze 36 pleural effusion samples and 22 matched biopsy tumor tissues collected from NSCLC patients. For each pleural effusion sample, the supernatant and the cell pellets were examined separately. Among all the 36 cases of pleural effusion samples, 18 mutations of EGFR were found in cell-free supernatant while 13 mutations were found in the cell pellets as detected by HRM analysis. In the 22 matched samples, 13 cases of EGFR mutations were identified in paraffin-embedded biopsy tissue samples, 12 cases in the cell-free supernatant and 9 cases in the cell pellets of pleural effusion. EGFR mutations in 15 cases out of the total 36 pleural effusion samples detected by direct sequencing were also identified by HRM analysis, giving 100% efficiency for HRM method. The results established the important role of HRM as a reliable and efficient method to determine EGFR mutation status and indicated the feasibility of using pleural effusion in replacement of biopsy tissues in particular clinical cases. Furthermore, the cell-free supernatant of pleural effusion might be a better resource for mutation detection than cell pellets.
机译:为了确定晚期非小细胞肺癌(NSCLC)患者的表皮生长因子受体(EGFR)突变并比较不同样品资源之间的检测效率,同时使用高分辨率熔解(HRM)分析和直接测序方法分析了36例胸膜癌。从非小细胞肺癌患者中收集的积液样本和22份匹配的活检肿瘤组织。对于每个胸腔积液样品,分别检查上清液和细胞沉淀。根据HRM分析,在36例胸腔积液样本中,无细胞上清液中发现了18个EGFR突变,而在细胞沉淀中发现了13个突变。在22个匹配的样本中,在石蜡包埋的活检组织样本中鉴定出13例EGFR突变,在无细胞上清液中鉴定出12例,在胸腔积液细胞沉淀中鉴定出9例。通过HRM分析还鉴定了直接测序检测到的36例胸腔积液样本中的15例EGFR突变,HRM方法的效率为100%。结果确立了HRM作为确定EGFR突变状态的可靠而有效的方法的重要作用,并表明在特定的临床病例中使用胸腔积液代替活检组织的可行性。此外,无胸腔积液的无细胞上清液可能比细胞沉淀物更好地用于突变检测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号